文献速递呼吸危重症与机械通气

吸入一氧化氮与依前列醇在急性呼吸衰竭中的比较:一项观察性目标试验模拟

Inhaled Nitric Oxide vs Epoprostenol During Acute Respiratory Failure: An Observational Target Trial Emulation.
PubMed 文献 · Chest · 2022-08-08

本研究利用美国大型数据库,纳入11,200例接受机械通气的急性呼吸衰竭或ARDS成人患者,比较初始吸入一氧化氮与依前列醇的实践模式及有效性。通过限制分析仅使用单一药物的医院,发现两组成功拔管可能性无差异(sHR 0.97,95%CI 0.80-1.18),住院总费用和死亡亦无差异。

要点

  • 美国医院间初始吸入血管扩张剂选择存在较大差异。
  • 仅用一氧化氮与仅用依前列醇的医院间成功拔管率无差异。
  • 两种药物在住院总费用和死亡风险上未见差异。

核心结论

  • 初始吸入一氧化氮与依前列醇在严重急性呼吸衰竭患者中成功拔管可能性无差异。

研究设计与样本

  • 观察性目标试验模拟,利用Premier Healthcare Database识别接受机械通气并启用吸入一氧化氮、依前列醇或两者的成人ARF或ARDS患者。

主要发现

  • 6,366例(56.8%)首先接受吸入一氧化氮,4,720例(42.1%)首先接受吸入依前列醇,114例(1.0%)同日接受两种治疗。
  • 仅用一氧化氮医院与仅用依前列醇医院的患者成功拔管可能性无差异(sHR 0.97;95%CI 0.80-1.18)。
  • 两组住院总费用和死亡风险均无差异,结果经多项敏感性分析稳健。

临床怎么用

  • 对于严重急性呼吸衰竭的机械通气患者,初始吸入血管扩张剂的选择可不拘泥于某一药物,因两者有效性相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The inhaled vasodilators nitric oxide and epoprostenol may be initiated to improve oxygenation in mechanically ventilated patients with severe acute respiratory failure (ARF); however, practice patterns and head-to-head comparisons of effectiveness are unclear. RESEARCH QUESTION: What are the practice patterns and comparative effectiveness for inhaled nitric oxide and epoprostenol in severe ARF? STUDY DESIGN AND METHODS: Using a large US database (Premier Healthcare Database), we identified adult patients with ARF or ARDS who were mechanically ventilated and started on inhaled nitric oxide, epoprostenol, or both. Leveraging large hospital variation in the choice of initial inhaled vasodilator, we compared the effectiveness of inhaled nitric oxide with that of epoprostenol by limiting analysis to patients admitted to hospitals that exclusively used either inhaled nitric oxide or epoprostenol. The primary outcome of successful extubation was modeled using multivariate Fine-Grey competing risk (death or hospice discharge) time-to-event models. RESULTS: Among 11,200 patients (303 hospitals), 6,366 patients (56.8%) received inhaled nitric oxide first, 4,720 patients (42.1%) received inhaled epoprostenol first, and 114 patients (1.0%) received both therapies on the same day. One hundred four hospitals (34.3%; 1,666 patients) exclusively used nitric oxide and 118 hospitals (38.9%; 1,812 patients) exclusively used epoprostenol. No differences were found in the likelihood of successful extubation between patients admitted to nitric oxide-only hospitals vs those admitted to epoprostenol-only hospitals (subdistribution hazard ratio, 0.97; 95% CI, 0.80-1.18). Also no differences were found in total hospital costs or death. Results were robust to multiple sensitivity analyses. INTERPRETATION: Large variation exists in the use of initial inhaled vasodilator for respiratory failure across US hospitals. Comparative effectiveness analyses identified no differences in outcomes based on inhaled vasodilator type.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Bosch NA, Law AC, Vail EA, et al. Inhaled Nitric Oxide vs Epoprostenol During Acute Respiratory Failure: An Observational Target Trial Emulation. Chest. 2022. PMID: 35952768. doi:10.1016/j.chest.2022.08.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。